SG11202011162RA - Circular rna for translation in eukaryotic cells - Google Patents

Circular rna for translation in eukaryotic cells

Info

Publication number
SG11202011162RA
SG11202011162RA SG11202011162RA SG11202011162RA SG11202011162RA SG 11202011162R A SG11202011162R A SG 11202011162RA SG 11202011162R A SG11202011162R A SG 11202011162RA SG 11202011162R A SG11202011162R A SG 11202011162RA SG 11202011162R A SG11202011162R A SG 11202011162RA
Authority
SG
Singapore
Prior art keywords
translation
eukaryotic cells
circular rna
rna
circular
Prior art date
Application number
SG11202011162RA
Inventor
Daniel G Anderson
Robert Alexander Wesselhoeft
Piotr S Kowalski
Original Assignee
Massachusetts Inst Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Inst Technology filed Critical Massachusetts Inst Technology
Publication of SG11202011162RA publication Critical patent/SG11202011162RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8527—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic for producing animal models, e.g. for tests or diseases
    • C12N2015/859—Animal models comprising reporter system for screening tests
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/20—Pseudochromosomes, minichrosomosomes
    • C12N2800/202—Pseudochromosomes, minichrosomosomes of bacteriophage origin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/50—Vectors for producing vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/70—Vectors containing special elements for cloning, e.g. topoisomerase, adaptor sites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/55—Vectors comprising a special translation-regulating system from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/60—Vectors comprising a special translation-regulating system from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2999/00—Further aspects of viruses or vectors not covered by groups C12N2710/00 - C12N2796/00 or C12N2800/00
    • C12N2999/007—Technological advancements, e.g. new system for producing known virus, cre-lox system for production of transgenic animals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
SG11202011162RA 2018-06-06 2019-06-05 Circular rna for translation in eukaryotic cells SG11202011162RA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862681617P 2018-06-06 2018-06-06
US201962791028P 2019-01-10 2019-01-10
US201962851548P 2019-05-22 2019-05-22
PCT/US2019/035531 WO2019236673A1 (en) 2018-06-06 2019-06-05 Circular rna for translation in eukaryotic cells

Publications (1)

Publication Number Publication Date
SG11202011162RA true SG11202011162RA (en) 2020-12-30

Family

ID=67253953

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202011162RA SG11202011162RA (en) 2018-06-06 2019-06-05 Circular rna for translation in eukaryotic cells

Country Status (12)

Country Link
US (6) US20200080106A1 (en)
EP (1) EP3801639A1 (en)
JP (1) JP2021526792A (en)
KR (1) KR20210018323A (en)
CN (1) CN112399860A (en)
AU (2) AU2019280583B2 (en)
BR (1) BR112020024292A2 (en)
CA (1) CA3100276A1 (en)
IL (1) IL279157A (en)
MX (1) MX2020013236A (en)
SG (1) SG11202011162RA (en)
WO (1) WO2019236673A1 (en)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA51155A (en) 2017-12-15 2020-10-21 Flagship Pioneering Innovations Vi Llc COMPOSITIONS CONSISTING OF CIRCULAR POLYRIBONUCLEOTIDES AND THEIR USES
CN112399860A (en) 2018-06-06 2021-02-23 麻省理工学院 Circular RNA for translation in eukaryotic cells
CA3139032A1 (en) 2019-05-22 2020-11-26 Robert Alexander WESSELHOEFT Circular rna compositions and methods
CN114096674A (en) * 2019-06-19 2022-02-25 旗舰创业创新第六有限责任公司 Method for administering cyclic polyribonucleotides
EP3920976B1 (en) 2019-12-04 2023-07-19 Orna Therapeutics, Inc. Circular rna compositions and methods
CN111297884B (en) * 2020-04-02 2021-03-30 中国农业科学院蜜蜂研究所 Application of adenosine in prevention and treatment of bee virus infection
CA3178111A1 (en) * 2020-05-08 2021-11-11 Brian Goodman Circular rna compositions and methods
US20230241212A1 (en) * 2020-06-30 2023-08-03 Nanjing Iaso Biotherapeutics Co., Ltd. Fully humanized bispecific chimeric antigen receptor targeting cd19 and cd22 and use thereof
JP2023531952A (en) 2020-07-01 2023-07-26 エレベートバイオ テクノロジーズ，インコーポレイテッド Compositions and methods for cellular reprogramming using circular RNA
CN111778281B (en) * 2020-07-17 2021-04-23 四川省人民医院 Construction method and application of retina bipolar cytopathy model
CN112481289B (en) * 2020-12-04 2023-06-27 苏州科锐迈德生物医药科技有限公司 Recombinant nucleic acid molecule for transcribing circular RNA and application of recombinant nucleic acid molecule in protein expression
CN114630909A (en) * 2020-12-04 2022-06-14 苏州科锐迈德生物医药科技有限公司 Cyclic RNA, vaccine comprising cyclic RNA and kit for detecting novel coronavirus neutralizing antibody
CN112725378B (en) * 2021-01-17 2022-10-04 昆明医科大学 Artificially-modified AKT3 circular RNA and application thereof in new corona vaccine
CN112877360B (en) * 2021-02-07 2023-06-27 中山大学附属第一医院 Construction method of circular RNA luciferase reporter plasmid for detecting IRES activity
EP4291229A1 (en) * 2021-02-09 2023-12-20 Virginia Commonwealth University Mini circular rna therapeutics and vaccines and methods of use thereof
WO2022191642A1 (en) * 2021-03-10 2022-09-15 알지노믹스 주식회사 Self-circularized rna structure
CN112941020B (en) * 2021-04-06 2023-03-10 广东海洋大学 Application of chicken circular RNA in promoting proliferation of myoblasts
CN113278635B (en) * 2021-05-25 2023-05-19 广州艾基生物技术有限公司 Sequence combination for promoting cyclic RNA (ribonucleic acid) to form ring and application thereof
CN115404240A (en) 2021-05-28 2022-11-29 上海环码生物医药有限公司 Constructs, methods for making circular RNA and uses thereof
CN115433733A (en) * 2021-06-04 2022-12-06 生物岛实验室 Cyclic RNA (ribonucleic acid) Circ-ACE2 translated polypeptide and application thereof
CN113344272B (en) * 2021-06-08 2022-06-21 汕头大学 Prediction method of interaction relation between circRNA, miRNA and RBP based on machine learning
CA3219932A1 (en) * 2021-06-10 2022-12-15 Robert Alexander WESSELHOEFT Circular rna compositions and methods
CN117916371A (en) 2021-07-27 2024-04-19 旗舰创业创新第六有限责任公司 Apparatus, system and method for processing
WO2023024500A1 (en) * 2021-08-27 2023-03-02 Peking University Constructs and methods for preparing circular rna
KR20230038627A (en) * 2021-09-07 2023-03-21 진원생명과학 주식회사 circular RNA and use thereof
CA3181628A1 (en) * 2021-11-16 2023-05-16 Martin Williams Circular rna platforms, uses theroeof, and their manufacturing processes from engineered dna
AR128002A1 (en) 2021-12-17 2024-03-20 Flagship Pioneering Innovations Vi Llc CIRCULAR RNA ENRICHMENT METHODS UNDER DENATURALING CONDITIONS
WO2023115732A1 (en) * 2021-12-21 2023-06-29 Peking University Single-pot methods for producing circular rnas
TW202340461A (en) * 2021-12-22 2023-10-16 美商旗艦先鋒創新有限責任公司 Compositions and methods for purifying polyribonucleotides
TW202342064A (en) 2021-12-23 2023-11-01 美商旗艦先鋒創新有限責任公司 Circular polyribonucleotides encoding antifusogenic polypeptides
WO2023143538A1 (en) * 2022-01-28 2023-08-03 北京辑因医疗科技有限公司 Method and composition for treating mpsi based on leaper technology
CN117417937A (en) * 2022-01-31 2024-01-19 奥明(杭州)生物医药有限公司 Cyclic RNA molecule and application thereof
CN114504658B (en) * 2022-02-25 2023-07-21 上海大学 Medicine for treating cardiotoxic injury induced by doxorubicin and application thereof
CN114574483A (en) * 2022-03-02 2022-06-03 苏州科锐迈德生物医药科技有限公司 Recombinant nucleic acid molecule based on point mutation of translation initiation element and application thereof in preparation of circular RNA
CN114438127B (en) * 2022-03-02 2024-03-19 苏州科锐迈德生物医药科技有限公司 Recombinant nucleic acid molecule and application thereof in preparation of circular RNA
CN114507691A (en) * 2022-03-02 2022-05-17 深圳市瑞吉生物科技有限公司 Carrier for preparing circular RNA and application thereof
CN114480499A (en) * 2022-03-04 2022-05-13 中国人民解放军陆军军医大学 Circular RNA molecule expression element and circular RNA molecule expression vector circEXPRO
CN114875053A (en) * 2022-03-11 2022-08-09 杭州师范大学 Construction method of efficient stable circular RNA and product thereof
WO2023182948A1 (en) 2022-03-21 2023-09-28 Bio Adventure Co., Ltd. Internal ribosome entry site (ires), plasmid vector and circular mrna for enhancing protein expression
WO2023195930A2 (en) * 2022-04-06 2023-10-12 Agency For Science, Technology And Research Vector for generating a circular rna
WO2023222114A1 (en) * 2022-05-20 2023-11-23 Innoforce Pharmaceuticals Methods of making circular rna
WO2023230549A2 (en) 2022-05-25 2023-11-30 Flagship Pioneering Innovations Vii, Llc Compositions and methods for modulation of tumor suppressors and oncogenes
WO2023230566A2 (en) 2022-05-25 2023-11-30 Flagship Pioneering Innovations Vii, Llc Compositions and methods for modulating cytokines
WO2023230578A2 (en) 2022-05-25 2023-11-30 Flagship Pioneering Innovations Vii, Llc Compositions and methods for modulating circulating factors
WO2023230573A2 (en) 2022-05-25 2023-11-30 Flagship Pioneering Innovations Vii, Llc Compositions and methods for modulation of immune responses
WO2023230570A2 (en) 2022-05-25 2023-11-30 Flagship Pioneering Innovations Vii, Llc Compositions and methods for modulating genetic drivers
WO2023242425A1 (en) 2022-06-17 2023-12-21 Sanofi Compositions and methods for circular rna affinity purification
WO2024010028A1 (en) * 2022-07-06 2024-01-11 国立大学法人京都大学 Circular rna molecule, and translation control method, translation activation system and pharmaceutical composition using same
CN115786374B (en) * 2022-07-06 2023-10-13 广州吉赛生物科技股份有限公司 Method for precisely preparing circular RNA by utilizing anabaena introns self-cleaving ribozyme
WO2024008189A1 (en) * 2022-07-08 2024-01-11 Shanghai Circode Biomed Co., Ltd. Methods and systems for purifying circular nucleic acids
WO2024054048A1 (en) * 2022-09-06 2024-03-14 알지노믹스 주식회사 Self-circularized rna structure
WO2024054047A1 (en) * 2022-09-06 2024-03-14 알지노믹스 주식회사 Self-circularization rna structure
US20240093185A1 (en) * 2022-09-10 2024-03-21 Exclcirc (Suzhou) Biomedical Co., Ltd. Circular rnas and preparation methods thereof
WO2024055941A1 (en) * 2022-09-13 2024-03-21 Suzhou Abogen Biosciences Co., Ltd. One-step method for synthesis of circular rna
CN116732039B (en) * 2023-08-03 2023-11-14 呈诺再生医学科技(北京)有限公司 Sequence combination for promoting RNA sequence to be cyclized and translated directly in cells and application thereof
CN117051043B (en) * 2023-10-11 2024-01-30 圆因(北京)生物科技有限公司 Methicillin-resistant staphylococcus aureus endolysin based on cyclic RNA coding and application thereof
CN117431258A (en) * 2023-12-20 2024-01-23 上海元戊医学技术有限公司 Method for inducing reprogramming of human cells using reprogramming factor containing Tet1 gene

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2948884A1 (en) 1979-12-05 1981-06-11 Basf Ag, 6700 Ludwigshafen 2-HYDROXYPROPYLIMIDAZOLES, METHOD FOR THE PRODUCTION AND USE THEREOF AS OIL-SOLUBLE CORROSION INHIBITORS
US4661450A (en) 1983-05-03 1987-04-28 Molecular Genetics Research And Development Limited Partnership Molecular cloning of RNA using RNA ligase and synthetic oligonucleotides
US4664777A (en) 1984-07-30 1987-05-12 Exxon Research And Engineering Company Process for improving octane by the conversion of fused multi-ring aromatics and hydroaromatics to lower molecular weight compounds
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
AU683011B2 (en) 1992-01-13 1997-10-30 Duke University Enzymatic RNA molecules
US5283241A (en) 1992-08-28 1994-02-01 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
DK148292D0 (en) 1992-12-09 1992-12-09 Lundbeck & Co As H RELATIONS
US5591737A (en) 1992-12-17 1997-01-07 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
US6096880A (en) 1993-04-15 2000-08-01 University Of Rochester Circular DNA vectors for synthesis of RNA and DNA
US5773244A (en) 1993-05-19 1998-06-30 Regents Of The University Of California Methods of making circular RNA
US5434261A (en) 1993-07-26 1995-07-18 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
PL314003A1 (en) 1993-10-19 1996-08-05 Merck & Co Inc Combination of bisulphonates and substances enhancing secretion of growth hormone
AU686780B2 (en) 1994-03-11 1998-02-12 Merck & Co., Inc. Composition for the treatment of lung disease
CA2144940A1 (en) 1994-03-18 1995-09-19 Chikara Murakata Therapeutic agent for thrombocytopenia and indolocarbazole derivatives
US5656606A (en) 1995-02-17 1997-08-12 Merck & Co., Inc. Camphor compounds promote release of growth hormone
US5747485A (en) 1995-04-13 1998-05-05 Merck & Co., Inc. Substituted azetidiones as anti-inflammatory and antidegenerative agents
US5766903A (en) 1995-08-23 1998-06-16 University Technology Corporation Circular RNA and uses thereof
GB2308064A (en) 1995-10-31 1997-06-18 Merck & Co Inc Treatment of congestive heart failure with a growth hormone secretagogue
GB2324726A (en) 1997-05-01 1998-11-04 Merck & Co Inc Combination Therapy for the Treatment of Osteoporosis
EP0897908A1 (en) 1997-08-19 1999-02-24 Roche Diagnostics GmbH 3-Aryl-succinamido-hydroxamic acids, process for their preparation and medicaments containing them
US6211174B1 (en) 1997-10-31 2001-04-03 Merck & Co., Inc. Naphtho-fused lactams promote release of growth hormone
EP1044281B1 (en) 1998-01-09 2006-11-22 University Of Utah Research Foundation Method for in vitro amplification of circular dna
US6210931B1 (en) 1998-11-30 2001-04-03 The United States Of America As Represented By The Secretary Of Agriculture Ribozyme-mediated synthesis of circular RNA
EP1282697B1 (en) 2000-03-28 2007-10-24 Queensland University of Technology A construct capable of release in closed circular form from a larger nucleotide sequence permitting site specific expression and/or developmentally regulated expression of selected genetic sequences
CA2543166A1 (en) 2003-10-24 2005-05-19 Auspex Pharmaceuticals, Inc. Ph sensitive prodrugs of 2,6-diisopropylphenol
WO2005079803A1 (en) 2004-02-13 2005-09-01 Pfizer Products, Inc. Compounds for treatment of cardiovascular diseases
US7786153B2 (en) 2005-03-02 2010-08-31 Abbott Laboratories Inc. Compounds that are useful for improving pharmacokinetics
CA2611944A1 (en) 2005-06-15 2006-12-28 Massachusetts Institute Of Technology Amine-containing lipids and uses thereof
WO2007044627A2 (en) 2005-10-06 2007-04-19 Sloan Kettering Institute For Cancer Research Compositions and methods for delivery of interfering rna
CN101016264A (en) 2007-01-22 2007-08-15 西安新安医药科技有限公司 Nitroimidazole derivative for treatment, preparing method and use
JP5296328B2 (en) 2007-05-09 2013-09-25 独立行政法人理化学研究所 Single-stranded circular RNA and method for producing the same
WO2009035541A1 (en) 2007-09-10 2009-03-19 Merck & Co., Inc. Method of treating inherited severe neutropenia
WO2010084371A1 (en) 2009-01-26 2010-07-29 Mitoprod Novel circular interfering rna molecules
TWI574961B (en) 2009-05-27 2017-03-21 Ｐｔｃ治療公司 Methods for treating cancer and non-neoplastic conditions
US20120202801A1 (en) 2009-05-27 2012-08-09 Liangxian Cao Methods for treating breast cancer
US20120157402A1 (en) 2009-05-27 2012-06-21 Liangxian Cao Methods for treating brain tumors
WO2010138652A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating kaposi sarcoma
US20120157401A1 (en) 2009-05-27 2012-06-21 Ptc Therapeutics, Inc. Methods for treating neurofibromatosis
WO2010138685A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating prostate conditions
JP5267874B2 (en) 2009-07-24 2013-08-21 ソニー株式会社 Signal processing apparatus and signal processing method
KR20110095439A (en) 2010-02-19 2011-08-25 건국대학교 산학협력단 Ammonium imidazolium salt and electrolyte composition for dye-sensitized sollar cells containing the salt
GB2496898B (en) 2011-11-25 2020-10-28 Petroliam Nasional Berhad Petronas Corrosion inhibition
JP6284181B2 (en) 2012-02-09 2018-02-28 国立研究開発法人理化学研究所 Method for producing circular RNA and protein
MY174813A (en) 2013-03-15 2020-05-16 Zymeworks Inc Cytotoxic and anti-mitotic compounds, and methods of using the same
JP6625521B2 (en) * 2013-05-15 2020-01-08 リボカイン，エルエルシー Intracellular translation of circular RNA
EP3017013A4 (en) 2013-05-28 2017-01-25 Yanjie Xu Refrigeration system with dual refrigerants and liquid working fluids
US8805972B1 (en) 2013-06-26 2014-08-12 Kaspersky Lab Zao Multi-platform operational objective configurator for computing devices
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
PT3083556T (en) 2013-12-19 2020-03-05 Novartis Ag Lipids and lipid compositions for the delivery of active agents
WO2016020373A1 (en) 2014-08-06 2016-02-11 Ascendis Pharma A/S Prodrugs comprising an aminoalkyl glycine linker
JP6912384B2 (en) * 2015-04-22 2021-08-04 キュアバック アーゲー RNA-containing compositions for the treatment of cancer diseases
AU2016271519B2 (en) 2015-06-05 2021-09-02 Dana-Farber Cancer Institute, Inc. Compositions and methods for transient gene therapy with enhanced stability
US10501768B2 (en) 2015-07-13 2019-12-10 Curevac Ag Method of producing RNA from circular DNA and corresponding template DNA
CA2994829A1 (en) 2015-08-07 2017-02-16 Seattle Children's Hospital (dba Seattle Children's Research Institute) Bispecific car t-cells for solid tumor targeting
JP6685039B2 (en) 2015-08-26 2020-04-22 国立大学法人東北大学 Compound, ionic liquid, platinum group element extractant, platinum group element extraction method
LU92830B1 (en) 2015-09-15 2017-04-03 Luxembourg Inst Of Health Lih Biomarkers for heart failure
CN105176981B (en) 2015-09-17 2017-03-15 广州永诺健康科技有限公司 DNA sequence and expression vector and its application for circular rna expression
AU2016324310B2 (en) 2015-09-17 2021-04-08 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
WO2017055487A2 (en) 2015-09-29 2017-04-06 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft A METHOD FOR DIAGNOSING A DISEASE BY DETECTION OF circRNA IN BODILY FLUIDS
EP3355926A4 (en) 2015-09-30 2019-08-21 Vertex Pharmaceuticals Inc. Method for treating cancer using a combination of dna damaging agents and atr inhibitors
PL3718565T3 (en) 2015-10-22 2022-09-19 Modernatx, Inc. Respiratory virus vaccines
EP3399983A1 (en) 2016-01-08 2018-11-14 The Institute of Cancer Research: Royal Cancer Hospital Inhibitors of ataxia-telangiectasia mutated and rad3-related protein kinase (atr) for use in methods of treating cancer
US20190106682A1 (en) * 2016-03-31 2019-04-11 Takeda Vaccines, Inc. Live, Attenuated Alphavirus Constructs and Methods and Uses Thereof
JP7210287B2 (en) 2016-05-18 2023-01-23 モダーナティエックス・インコーポレイテッド Polynucleotides encoding citrine for the treatment of type II citrullinemia
US20190275170A1 (en) 2016-05-18 2019-09-12 Modernatx, Inc. Polynucleotides encoding jagged1 for the treatment of alagille syndrome
CA3024624A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding porphobilinogen deaminase for the treatment of acute intermittent porphyria
WO2017201332A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding acyl-coa dehydrogenase, very long-chain for the treatment of very long-chain acyl-coa dehydrogenase deficiency
KR102469450B1 (en) 2016-05-18 2022-11-22 모더나티엑스, 인크. Polynucleotides Encoding Interleukin-12 (IL12) and Uses Thereof
CA3024500A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding relaxin
US20190390181A1 (en) 2016-05-18 2019-12-26 Modernatx, Inc. Polynucleotides Encoding Lipoprotein Lipase for the Treatment of Hyperlipidemia
WO2017201348A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding galactose-1-phosphate uridylyltransferase for the treatment of galactosemia type 1
US11814627B2 (en) * 2016-06-20 2023-11-14 The Board Of The Leland Stanford Junior University Circular RNAs and their use in immunomodulation
US20180010175A1 (en) 2016-09-22 2018-01-11 Bio-Rad Laboratories, Inc. Methods and compositions for cloning circular rna
BR112019008369A2 (en) 2016-10-26 2019-10-01 Modernatx Inc messenger ribonucleic acids to enhance immune responses and methods for using them
US20190290694A1 (en) 2016-12-21 2019-09-26 Cellectis Stably enginereed proteasome inhibitor resistant immune cells for immunotherapy
KR20190110612A (en) 2017-02-01 2019-09-30 모더나티엑스, 인크. Immunomodulatory Therapeutic MRNA Compositions Encoding Activating Oncogene Mutant Peptides
CN106801050B (en) 2017-02-20 2020-01-14 广州永诺生物科技有限公司 Construction method of circular RNA high-throughput sequencing library and kit thereof
US20200368162A1 (en) 2017-02-24 2020-11-26 Modernatx, Inc. Nucleic Acid-Based Therapy of Muscular Dystrophies
HUE060693T2 (en) 2017-03-15 2023-04-28 Modernatx Inc Compound and compositions for intracellular delivery of therapeutic agents
WO2018170260A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Respiratory syncytial virus vaccine
EP3610035A4 (en) 2017-04-14 2021-06-09 Dana-Farber Cancer Institute, Inc. Compositions and methods for transient gene therapy with enhanced stability
WO2018220583A1 (en) 2017-05-31 2018-12-06 Vilnius University Production of cyclic adenylates and their use as allosteric regulators
EP3642342A4 (en) 2017-06-23 2021-03-17 Cornell University Rna molecules, methods of producing circular rna, and treatment methods
MA51155A (en) * 2017-12-15 2020-10-21 Flagship Pioneering Innovations Vi Llc COMPOSITIONS CONSISTING OF CIRCULAR POLYRIBONUCLEOTIDES AND THEIR USES
WO2019213308A1 (en) 2018-05-01 2019-11-07 Fred Hutchinson Cancer Research Center Nanoparticles for gene expression and uses thereof
WO2019222275A2 (en) 2018-05-14 2019-11-21 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using inducible fusion proteins
CN112399860A (en) 2018-06-06 2021-02-23 麻省理工学院 Circular RNA for translation in eukaryotic cells
WO2020010242A1 (en) 2018-07-03 2020-01-09 Washington State University Pharmaceutical agents for use in smoking and tobacco cessation
JP7283669B2 (en) 2018-08-17 2023-05-30 チャンチョウ ピエン ツェ フアン ファーマシューティカル カンパニー リミテッド 3-Aryloxy-3-aryl-propylamine compounds and uses thereof
CA3113436A1 (en) 2018-09-19 2020-03-26 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
KR20210142678A (en) 2019-03-25 2021-11-25 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 Compositions comprising modified circular polyribonucleotides and uses thereof
CA3139032A1 (en) 2019-05-22 2020-11-26 Robert Alexander WESSELHOEFT Circular rna compositions and methods
AU2020292427A1 (en) 2019-06-14 2022-01-06 Flagship Pioneering Innovations Vi, Llc Circular RNAs for cellular therapy
US20220288176A1 (en) 2019-08-28 2022-09-15 The Board Of Trustees Of The Leland Stanford Junior University Circular rna modification and methods of use
AU2020351225A1 (en) 2019-09-19 2022-04-07 Modernatx, Inc. Headgroup lipid compounds and compositions for intracellular delivery of therapeutic agents
JP2022548304A (en) 2019-09-19 2022-11-17 モデルナティエックス インコーポレイテッド Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
EP3819377A1 (en) 2019-11-08 2021-05-12 Justus-Liebig-Universität Gießen Circular rna and uses thereof for inhibiting rna-binding proteins
EP3920976B1 (en) 2019-12-04 2023-07-19 Orna Therapeutics, Inc. Circular rna compositions and methods

Also Published As

Publication number Publication date
AU2019280583A1 (en) 2020-12-03
US20230050306A1 (en) 2023-02-16
US20220025395A1 (en) 2022-01-27
US11352641B2 (en) 2022-06-07
IL279157A (en) 2021-01-31
CA3100276A1 (en) 2019-12-12
US11447796B2 (en) 2022-09-20
BR112020024292A2 (en) 2021-03-02
CN112399860A (en) 2021-02-23
KR20210018323A (en) 2021-02-17
US11203767B2 (en) 2021-12-21
US20210363540A1 (en) 2021-11-25
US20200080106A1 (en) 2020-03-12
AU2019280583B2 (en) 2022-12-15
AU2023201630A1 (en) 2023-04-13
US20210403944A1 (en) 2021-12-30
EP3801639A1 (en) 2021-04-14
US11845950B2 (en) 2023-12-19
WO2019236673A1 (en) 2019-12-12
US20210198688A1 (en) 2021-07-01
JP2021526792A (en) 2021-10-11
MX2020013236A (en) 2021-02-22
US11352640B2 (en) 2022-06-07

Similar Documents

Publication Publication Date Title
IL279157A (en) Circular rna for translation in eukaryotic cells
GB201813178D0 (en) Cell
GB201611982D0 (en) Cell culture
GB201712733D0 (en) Methods & cells
GB201803079D0 (en) Cell
SG11202004935UA (en) Cell culture methods
EP3342414A4 (en) Agent for enhancing atp in cells
EP3380102A4 (en) Telomere extension and anti-inflammatory agents for cell regeneration
IL283819A (en) Cell isolation for use in automated bioreactors
IL290590A (en) Cell culture methods
EP3448986A4 (en) Cell culture
IL270880A (en) Cell culture methods
GB201904971D0 (en) Cell
GB201710655D0 (en) Electrochemical cell
GB201906202D0 (en) Cell
CA185441S (en) Cell culture insert
GB201807693D0 (en) Cell
PL3287521T3 (en) Cell culture
EP4048783C0 (en) Modified cell
CA185442S (en) Cell culture insert
GB201816399D0 (en) Cell
GB201805918D0 (en) Cell
HUE045129T2 (en) Back sheet for solar cell
IL274191A (en) Eukaryotic cell line
GB2577995B (en) Cell